Collegium Pharmaceutical (NASDAQ:COLL) Shareholders Have Earned a 19% CAGR Over the Last Five Years

Yahoo FinanceJun 20 07:09 ET

Express News | Collegium Pharmaceutical Announces FDA Grant Of Pediatric Exclusivity For Nucynta Franchise; Extends U.S. Exclusivity To January 2027 For Nucynta And December 2025 For Nucynta ER

BenzingaJun 13 08:05 ET

Express News | Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise

ReutersJun 13 08:04 ET

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu

Simply Wall StJun 11 07:34 ET

Street Calls of the Week: Upgrades for Best Buy and Lululemon

Yahoo FinanceJun 9 01:07 ET

Collegium Pharmaceutical Price Target Raised to $44.00/Share From $41.00 by Jefferies

Collegium Pharmaceutical Price Target Raised to $44.00/Share From $41.00 by Jefferies

Dow JonesJun 7 13:05 ET